paroxetine has been researched along with Mood Disorders in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 14 (51.85) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, C; Komahashi-Sasaki, H; Maehara, R; Shimoda, K; Yasui-Furukori, N | 1 |
| Balestrieri, M; Castelpietra, G; De Vido, C; Gobbato, M; Isacsson, G; Valent, F | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Belcher, DC; Dowben, JS; Keltner, NL; Kowalski, PC | 1 |
| Amodeo, LR; Crawford, CA; Eaton, SE; Greenfield, VY; Harmony, ZR; Humphrey, DE; Johnson, JD; Pipkin, JA; Plant, CP; Varela, V; Wang, L | 1 |
| Funato, H; Hobara, T; Matsubara, T; Matsuo, K; Otsuki, K; Suetsugi, M; Uchida, S; Watanabe, Y | 1 |
| Demetrashvili, MF; Liu, S; Manatunga, A; McNutt, MD; Miller, AH; Musselman, DL; Raison, CL; Royster, EB; Woolwine, BJ | 1 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Arbuzov, AL; Khurbatova, IG; Kutushev, OT; Litvintsev, SV; Martyniuk, IuL; Reznik, AM | 1 |
| Wooltorton, E | 1 |
| Nemeroff, CB | 1 |
| Kilts, C | 1 |
| Yonkers, KA | 1 |
| Wagner, KD | 1 |
| Artioli, P; Cusin, C; Dotoli, D; Rossini, D; Serretti, A; Zanardi, R | 1 |
| Fujimura, Y; Suhara, T | 1 |
| Benedetti, F; Colombo, C; Cusin, C; Mandelli, L; Pirovano, A; Serretti, A; Smeraldi, E; Zanardi, R | 1 |
| Carrasco, JL; Sandner, C | 1 |
| Bertschy, G; Bondolfi, G; Golaz, J; Rachid, F | 1 |
| Barnhill, LJ; Horrigan, JP | 1 |
| Erfurth, A | 1 |
| Grimes, JB; Hines, A; Labbate, LA; Pollack, MH | 1 |
| Liebowitz, MR | 1 |
| Hensley, PL; Nurnberg, HG; Thompson, PM | 1 |
| Antonietti, M; Denis, P; Ducrotte, P; Lalaude, O; Leroi, AM; Menard, JF; Touchais, JY | 1 |
| Emslie, GJ; Mayes, TL | 1 |
| Capuron, L; Gumnick, JF; Lawson, DH; Miller, AH; Musselman, DL; Nemeroff, CB; Reemsnyder, A | 1 |
6 review(s) available for paroxetine and Mood Disorders
| Article | Year |
|---|---|
Biological Perspectives: Huntington's Disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Cognition Disorders; Dementia; Humans; Huntington Disease; Magnetic Resonance Imaging; Male; Memory, Short-Term; Mood Disorders; Olanzapine; Paroxetine | 2015 |
In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Electroencephalography; Humans; Magnetic Resonance Imaging; Mood Disorders; Paroxetine; Tomography, Emission-Computed, Single-Photon | 2003 |
Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
Topics: Antidepressive Agents, Second-Generation; Female; Hot Flashes; Humans; Menopause; Mood Disorders; Paroxetine; Premenstrual Syndrome | 2003 |
[Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors].
Topics: Amoxapine; Animals; Antidepressive Agents, Second-Generation; Brain; Humans; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Mood Disorders; Nerve Tissue Proteins; Paroxetine; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Receptors, Serotonin, 5-HT2; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Trazodone | 2004 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Update on the diagnosis and treatment of social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Female; Humans; Male; Mental Disorders; Mood Disorders; Paroxetine; Phobic Disorders; Quality of Life; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
6 trial(s) available for paroxetine and Mood Disorders
| Article | Year |
|---|---|
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2012 |
[Correction of affective disorders in patients with alcohol dependence].
Topics: Adult; Alcoholism; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Humans; Middle Aged; Military Personnel; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; DNA; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Mood Disorders; Nerve Tissue Proteins; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Tryptophan Hydroxylase | 2004 |
Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism.
Topics: Adult; Aged; Antidepressive Agents; CLOCK Proteins; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Gene Frequency; Genotype; Humans; Male; Middle Aged; Mood Disorders; Multivariate Analysis; Paroxetine; Pindolol; Polymorphism, Genetic; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Time Factors; Trans-Activators; Treatment Outcome | 2005 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Medical Records; Mental Disorders; Middle Aged; Mood Disorders; Paroxetine; Retrospective Studies; Sampling Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Chi-Square Distribution; Double-Blind Method; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Mood Disorders; Neoplasms; Paroxetine; Patients; Statistics, Nonparametric | 2002 |
15 other study(ies) available for paroxetine and Mood Disorders
| Article | Year |
|---|---|
A case of mood disorder with severe side effects of antidepressants in association with resistance to thyroid hormone beta with a THRB mutation.
Topics: Aged; Antidepressive Agents; Female; Humans; Mirtazapine; Mood Disorders; Mutation; Paroxetine; Quetiapine Fumarate; Thyroid Hormone Receptors beta; Thyroid Hormone Resistance Syndrome; Thyroid Hormones; Venlafaxine Hydrochloride | 2022 |
Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005-2014.
Topics: Antidepressive Agents; Case-Control Studies; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Suicide Prevention | 2017 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Male; Maze Learning; Mood Disorders; Paroxetine; Rats; Rats, Sprague-Dawley; Sensory Gating; Treatment Outcome | 2015 |
Altered gene expression of histone deacetylases in mood disorder patients.
Topics: Animals; Antidepressive Agents; Clomipramine; Corticotropin-Releasing Hormone; Dexamethasone; Disease Models, Animal; Female; Gene Expression Regulation; Histone Deacetylases; Humans; Hydrocortisone; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Mood Disorders; Paroxetine; RNA, Messenger; Swimming | 2010 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |
Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients.
Topics: Adolescent; Child; Contraindications; Humans; Mood Disorders; Paroxetine; Pediatrics; Risk; Selective Serotonin Reuptake Inhibitors; Suicide | 2003 |
Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Humans; Mood Disorders; Paroxetine | 2003 |
Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, Major; Humans; Mood Disorders; Paroxetine; Phobic Disorders | 2003 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Female; Humans; Methadone; Mood Disorders; Narcotics; Opipramol; Paroxetine; Prazepam; Psychiatric Status Rating Scales; Serotonin Syndrome; Severity of Illness Index; Substance-Related Disorders; Transcranial Magnetic Stimulation; Trazodone; Valproic Acid | 2006 |
Paroxetine-pimozide drug interaction.
Topics: Albinism; Attention Deficit Disorder with Hyperactivity; Blindness; Child; Drug Synergism; Enuresis; Humans; Male; Mood Disorders; Obsessive-Compulsive Disorder; Paroxetine; Pimozide | 1994 |
[Therapy of affect incontinence with paroxetine].
Topics: Antidepressive Agents, Second-Generation; Cerebral Infarction; Female; Humans; Middle Aged; Mood Disorders; Neurocognitive Disorders; Paroxetine | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Drug Therapy, Combination; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Mood Disorders; Pain Measurement; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 1997 |
Prolonged stationary colonic motility recording in seven patients with severe constipation secondary to antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Cathartics; Cholinergic Antagonists; Clomipramine; Colon; Colonoscopy; Constipation; Depressive Disorder; Eating; Fecal Impaction; Female; Gastrointestinal Motility; Humans; Male; Manometry; Maprotiline; Middle Aged; Mood Disorders; Muscle Contraction; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiazepines; Viloxazine | 2000 |
Mood disorders in children and adolescents: psychopharmacological treatment.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Health Services Needs and Demand; Humans; Imipramine; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |